Recro Pharma, Inc. (NASDAQ:REPH) Q1 2019 Earnings Conference Call Transcript

May 10, 2019 • 08:00 am ET


Recro Pharma, Inc. (NASDAQ:REPH) Q1 2019 Earnings Conference Call Transcript


Loading Event

Loading Transcript


Good morning and welcome to the Recro Pharma First Quarter 2019 Financial Results Conference Call. At this time all participants are in listen-only mode. Latter, we will conduct a question-and-answer session and instructions will be given at that time. As a reminder, this conference is being recorded at the company's request.

I would now like to turn the call over to Claudia Styslinger, Investor Relations. You may begin.

Claudia Styslinger

Good morning, and thank you for joining us on today's conference call to discuss Recro's first quarter 2019 financial results. This is Claudia Styslinger, and I'm joined today by Gerri Henwood, President and Chief Executive Officer; and Ryan Lake, Chief Financial Officer. Following prepared remarks today by Gerri and Ryan, we will open the call for questions.

Earlier this morning, we issued a press release detailing our financial and operating results for the three months ended March 31, 2019. The press release is available on the news and Investors page of our website at

Before we begin our formal comments, I'll remind you that various remarks we make today constitute forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements related to our financial outlook, our ability to raise capital on terms acceptable to us, our ability to resolve the Complete Response Letter issued by the US Food and Drug Administration on our New Drug Application for IV meloxicam and the time frame associated with such resolution, and our product development plans for our other products candidates, including the results and timing of any future preclinical studies and clinical trials for such product candidates.

These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from our expectations and forecasts and can be identified by words such as expect, plan, will, may, anticipate, believe, estimate, upcoming, should, intend and any words of other similar meaning. Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties. These risks are described in the risk factors and management's discussion and analysis of financial condition and results of operations sections of Recro Pharma's Annual Report on Form 10-K for the fiscal year ended December 31, 2018, and any quarterly reports on Form 10-Q, which are on file with the Securities and Exchange Commission and available on the SEC's website.

Any information we provide on this conference call is provided only as of the day of this call, May 10, 2019, and we undertake no obligation to update any forward-looking statements we may make on this call on account of new information, future events or otherwise. In addition, any unaudited or pro forma financial information that may be provided is preliminary and does not purport to project financial positions or operating results of the company. Actual results may differ materially.

We may also discuss certain non-GAAP financial measures with respect to our financial performance for the three months ended March 31, 2019. Specifically, we may discuss